Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Isodiol International Inc. (ISOLF)
Vancouver, BC, CA
Isodiol International Inc. (ISOLF) is a company dedicated to the full spectrum of developing, marketing, distributing, and selling consumer products derived from hemp, alongside related solutions. Its operations span across Canada and the United States. The company focuses on creating and producing specialized consumer phytoceuticals, utilizing pharmaceutical and nutraceutical grade phytochemical compounds. Additionally, Isodiol provides high-purity, pharmaceutical-grade crystalline cannabinoid isolates, which are extracted from non-restricted parts of the hemp plant. It also incorporates advanced delivery systems, such as micro-encapsulation and nanotechnology, into both consumable and topical skincare products. Isodiol's comprehensive product line further includes the manufacturing and distribution of hemp oil and nicotine e-liquids, various personal care items, and distinctive apparel and merchandising solutions. The company also produces and sells hemp-infused beverages and acts as a supplier of pharmaceutical products. Its corporate headquarters are located in Vancouver, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +9,900.00% | +0.00% | +0.00% | +900.00% | +0.00% | -99.98% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+12.2% ★ Q4'19: -85.0% (vs Q4'18)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-76.7% Q4'19: +96.2% (vs Q4'18)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-547.2% Q4'19: +17.7% (vs Q4'18)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-516.6% Q4'19: -64.6% (vs Q4'18)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-945.6% Q4'19: -91.2% (vs Q4'18)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+83.4% Q4'19: +22.5% (vs Q4'18)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.07× Q4'19: 0.00× (vs Q4'18)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Patrick Edward Ogle | Chief Operating Officer & Director | 243.4K | male |
| Marcos Agramont | Chief Executive Officer & Director | 230.5K | male |
| Soheil Samimi | Advisor | 37.6K | male |
| Marvin Washington | Vice President & Director of Business Development and Director | 9.6K | male |
| Andrew Stanton Alvis | President, Interim Chief Financial Officer & Director | — | male |
| Kevin W. Swadish | Chief Revenue Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ISOLF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
